CURE

Trial Supports MRI-guided TULSA Procedure for Prostate Cancer Safety

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...
Seeking Alpha

Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Medscape

MRI-Guided TULSA Shows Faster Recovery Than Robotic Prostatectomy in CAPTAIN Trial

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.
Seeking Alpha

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Business Insider

Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...
Nasdaq

Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...
Hosted on MSN

Profound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction Module

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

Profound Medical reports CAPTAIN trial meets primary safety endpoint

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...
AOL

Does Medicare cover TULSA-PRO?

Doctors perform transurethral ultrasound ablation (TULSA) procedures using the TULSA-PRO system. This treats people with prostate disease, including prostate cancer or an enlarged prostate. New ...
AOL

Is TULSA-PRO Covered by Medicare?

Transurethral ultrasound ablation (TULSA) procedures are performed using the TULSA-PRO system when treating people who have prostate disease, including an enlarged prostate and prostate cancer. There ...
ksn.com

Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment

TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company developing AI-powered, incision-free ...